StreetInsider.com News Articles

Form 6-K Evotec SE For: Jun 17

Wed, 17 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26656429.html

Form 6-K Evotec SE For: Jun 17

Wed, 17 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26656429.html

Form 6-K Evotec SE For: Jun 17

Wed, 17 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26656429.html

Evotec Reports Results of the Annual General Meeting 2026

Thu, 11 Jun 2026 12:02:00 -0400

11.06.2026 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

All agenda items adopted
Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board
Dieter Weinand appointed Chairman of the Supervisory Board
Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board

HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

All agenda items put to vote were adopted by the Company's shareholders with the required majority.

Shareholders elected Dieter Weinand

Evotec Reports Results of the Annual General Meeting 2026

Thu, 11 Jun 2026 12:02:00 -0400

11.06.2026 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

All agenda items adopted
Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board
Dieter Weinand appointed Chairman of the Supervisory Board
Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board

HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

All agenda items put to vote were adopted by the Company's shareholders with the required majority.

Shareholders elected Dieter Weinand

Evotec Reports Results of the Annual General Meeting 2026

Thu, 11 Jun 2026 12:02:00 -0400

11.06.2026 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

All agenda items adopted
Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board
Dieter Weinand appointed Chairman of the Supervisory Board
Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board

HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

All agenda items put to vote were adopted by the Company's shareholders with the required majority.

Shareholders elected Dieter Weinand

Evotec Reports Results of the Annual General Meeting 2026

Thu, 11 Jun 2026 12:02:00 -0400

11.06.2026 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

All agenda items adopted
Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board
Dieter Weinand appointed Chairman of the Supervisory Board
Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board

HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

All agenda items put to vote were adopted by the Company's shareholders with the required majority.

Shareholders elected Dieter Weinand

Evotec Reports Results of the Annual General Meeting 2026

Thu, 11 Jun 2026 12:02:00 -0400

11.06.2026 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

All agenda items adopted
Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board
Dieter Weinand appointed Chairman of the Supervisory Board
Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board

HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

All agenda items put to vote were adopted by the Company's shareholders with the required majority.

Shareholders elected Dieter Weinand

Evotec Reports Results of the Annual General Meeting 2026

Thu, 11 Jun 2026 12:02:00 -0400

11.06.2026 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

All agenda items adopted
Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board
Dieter Weinand appointed Chairman of the Supervisory Board
Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board

HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

All agenda items put to vote were adopted by the Company's shareholders with the required majority.

Shareholders elected Dieter Weinand

Evotec appoints Rui Wang as head of global in silico and AI

Tue, 02 Jun 2026 06:07:41 -0400

Evotec SE (NASDAQ: EVO) announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Wang brings over 20 years of experience supporting pharmaceutical and biotechnology organizations in implementing data, analytics and artificial intelligence across research and development, drug development, manufacturing and supply chain functions.

In his new role, Wang will lead the integration of computational science and data-driven decision-making across Evotec's R&D operations. The company stated the position aims to create enterprise-scale solutions that establish AI and in silico science as key components of Evotec's commercial value proposition.

Wang previously served as Head of Data,

Evotec appoints Rui Wang as head of global in silico and AI

Tue, 02 Jun 2026 06:07:41 -0400

Wang previously served as Head of Data,

Evotec Appoints Rui Wang as Head of Global In Silico and AI

Tue, 02 Jun 2026 01:45:00 -0400

HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions. In his role, Mr. Wang will spearhead the integration of computational science and data-driven decision-making across the R&D operation, with the goal of creating enterprise-scale solutions

Evotec Appoints Rui Wang as Head of Global In Silico and AI

Tue, 02 Jun 2026 01:45:00 -0400

Evotec SE raises €116.1 million through convertible bond placement

Tue, 12 May 2026 17:15:54 -0400

Evotec SE (NASDAQ: EVO) completed a placement of senior unsecured convertible bonds totaling €116.1 million, according to a company statement.

The bonds mature in seven years with an investor put option after five years and carry an annual interest rate of 2.625% paid semi-annually. Each bond has a denomination of €100,000 and will be repaid at 110% of principal amount at maturity, resulting in a yield to maturity of 3.882%.

The initial conversion price is set at €6.5313, representing a 37.5% premium above the reference share price of €4.75. The effective conversion price at maturity is approximately €7.1844 when accounting for the

Evotec SE Successfully Placed €116.1 Million Convertible Bonds

Tue, 12 May 2026 17:15:00 -0400

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

HAMBURG, GERMANY / ACCESS Newswire / May 12, 2026 / Evotec SE (the "Company" or "Evotec") (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) placed today senior unsecured convertible bonds due 2033, convertible into new and/or existing no-par value ordinary bearer shares of the Company (the "Shares"), in an aggregate principal amount

Evotec SE Successfully Placed €116.1 Million Convertible Bonds

Tue, 12 May 2026 17:15:00 -0400

Evotec AG (EVT:GR) (EVO) PT Lowered to EUR9.40 at Berenberg

Tue, 12 May 2026 05:46:47 -0400

Berenberg analyst Christian Ehmann lowered the price target on Evotec AG (EVT:GR) (NASDAQ: EVO) to EUR9.40 (from EUR9.70) while maintaining a Buy rating.

Evotec AG (EVT:GR) (EVO) PT Lowered to EUR9.40 at Berenberg

Tue, 12 May 2026 05:46:47 -0400

Berenberg analyst Christian Ehmann lowered the price target on Evotec AG (EVT:GR) (NASDAQ: EVO) to EUR9.40 (from EUR9.70) while maintaining a Buy rating.

Evotec AG (EVT:GR) (EVO) PT Lowered to EUR9.40 at Berenberg

Tue, 12 May 2026 05:46:47 -0400

Berenberg analyst Christian Ehmann lowered the price target on Evotec AG (EVT:GR) (NASDAQ: EVO) to EUR9.40 (from EUR9.70) while maintaining a Buy rating.

Evotec AG (EVT:GR) (EVO) PT Lowered to EUR9.40 at Berenberg

Tue, 12 May 2026 05:46:47 -0400

Berenberg analyst Christian Ehmann lowered the price target on Evotec AG (EVT:GR) (NASDAQ: EVO) to EUR9.40 (from EUR9.70) while maintaining a Buy rating.

Form 6-K Evotec SE For: May 06

Wed, 06 May 2026 09:39:00 -0400

si-local-file:///var/storage/secattach/20260506/26440752.html

Form 6-K Evotec SE For: May 06

Wed, 06 May 2026 09:39:00 -0400

si-local-file:///var/storage/secattach/20260506/26440752.html

Form 6-K Evotec SE For: May 06

Wed, 06 May 2026 09:39:00 -0400

si-local-file:///var/storage/secattach/20260506/26440752.html

Evotec nominates preclinical candidate from dermatology partnership

Mon, 04 May 2026 05:54:26 -0400

Evotec SE (NASDAQ: EVO) announced the nomination of a small molecule preclinical development candidate from its drug discovery collaboration with Almirall S.A., according to a company statement. The program targets immune-mediated inflammatory skin diseases.

The joint team progressed from initial leads to preclinical development candidate within two years, which the company stated compares favorably to typical industry timelines for similar small molecule programs. The collaboration combines Evotec's AI and machine learning-enhanced discovery platforms with Almirall's dermatology expertise.

Evotec will continue supporting the program toward investigational new drug submission through its INDiGO platform. The Hamburg-based company's Chief Scientific Officer Cord Dohrmann said the

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Mon, 04 May 2026 01:50:00 -0400

Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines
Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology expertise

HAMBURG, DE / ACCESS Newswire / May 4, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the nomination of a small molecule preclinical development candidate (PDC) from its multi‑target drug discovery alliance in medical dermatology with Almirall S.A. The program is aimed at developing novel treatments for immune‑mediated inflammatory skin diseases with high unmet medical need.

The nomination marks an important achievement for the collaboration, with